EW Q1 2023 Earnings — Edwards Lifesciences Corporation Revenue & Financial Results | Market Cap Arena

EWEdwards Lifesciences Corporation

$50B

Q1 2023 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$1.5B+8.8% YoY

Gross Profit

$1.1B75.4% margin

Operating Income

$403M27.6% margin

Net Income

$341M23.3% margin

EPS (Diluted)

$0.56

QoQ Revenue Growth

+8.3%

Cash Flow

Operating Cash Flow

$314M

Free Cash Flow

$253M

Stock-Based Comp.

$39M

Balance Sheet

Total Assets

$8.7B

Total Liabilities

$2.6B

Stockholders' Equity

$6.0B

Cash & Equivalents

$873M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.5B	$1.3B	+8.8%
Gross Profit	$1.1B	$1.0B	+6.4%
Operating Income	$403M	$436M	-7.6%
Net Income	$341M	$374M	-8.9%

Revenue Segments

Transcatheter Heart Valves

$948M65%

Surgical Heart Valve Therapy

$248M17%

Critical Care

$222M15%

Transcatheter Mitral And Tricuspid Therapies

$42M3%

Geographic Segments

UNITED STATES

$849M58%

Europe

$331M23%

Rest of World

$165M11%

JAPAN

$114M8%